Hyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease:: A pilot study

被引:35
作者
Cicero, AFG [1 ]
Brancaleoni, M [1 ]
Laghi, L [1 ]
Donati, F [1 ]
Mino, M [1 ]
机构
[1] Univ Bologna, Dept Internal Med & Appl Biotechnol, Atherosclerosis & Metab Dis Study Ctr G Descovich, S Orsola Malpighi Univ Hosp, I-40138 Bologna, Italy
关键词
D O I
10.1016/j.ctim.2005.07.008
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objectives: We planned to carry out a pilot study to evaluate the efficacy and safety as an anti hypercholesterolemic agent of a brand dietary supplement made of Monascus purpureus titrated extract, octacosanols and niacin on 111 Caucasian patients with low cardiovascular disease risk (<20% by Framingham algorithms), comparing them with the anti hypercholesterolemic effect of a Low dosage of Pravastatin on 20 subjects with similar risk profile. Results: In our study, the tested dietary supplement determined a significant decrease of Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG) in moderately hypercholesterolemic subjects without clinically relevant change in Liver and muscular toxicity markers. The reduction of LDL-C reached the 20%, and it is similar to that obtained with a well-known effective statin like Pravastatin. Conclusions: Further long-term and double blind evaluation have to be carried out before to infer the observed results, however it appears that the studied dietary supplements could be a safe and efficacious anti hypercholesterolemic agent for patients at tow risk for cardiovascular diseases. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:273 / 278
页数:6
相关论文
共 27 条
[1]   A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom [J].
Buller, N ;
Gillen, D ;
Casciano, R ;
Doyle, J ;
Wilson, K .
PHARMACOECONOMICS, 2003, 21 (Suppl 1) :25-32
[2]   Evaluation of the antihyperlipidemic properties of dietary supplements [J].
Caron, MF ;
White, CM .
PHARMACOTHERAPY, 2001, 21 (04) :481-487
[3]  
Castaño G, 2002, INT J CLIN PHARM RES, V22, P89
[4]   Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia [J].
Castaño, G ;
Mas, R ;
Fernández, L ;
Illnait, J ;
Mesa, M ;
Alvarez, E ;
Lezcay, M .
DRUGS & AGING, 2003, 20 (02) :153-163
[5]   Effects of policosanol and lovastatin in patients with intermittent claudication:: A double-blind comparative pilot study [J].
Castaño, G ;
Más, R ;
Fernández, L ;
Gámez, R ;
Illnait, J .
ANGIOLOGY, 2003, 54 (01) :25-38
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]   Niacin and cholesterol: role in cardiovascular disease (Review) [J].
Ganji, SH ;
Kamanna, VS ;
Kashyap, ML .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2003, 14 (06) :298-305
[8]  
Gotto A.M., 2003, Clin. Cardiol., V26, P21, DOI [10.1002/clc.4960261307, DOI 10.1002/CLC.4960261307]
[9]  
Heber D, 1999, AM J CLIN NUTR, V69, P231
[10]   Herbs and atherosclerosis. [J].
Heber D. .
Current Atherosclerosis Reports, 2001, 3 (1) :93-96